Clinical Trials

Clinical Trial Detail

Return to search results.

A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Complete title: A Phase I, Multicenter, Open-Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients with Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Research Study Number       20110186
    
Principal Investigator       Laura Chow
    
Phase       I

Look up trial at NIH

Research Study Description

This study will assess the safety and early efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK)

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Tumor must be confirmed to be ALK positive

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Pregnant

- Active pancreatitis

- Active or chronic liver disease

- Other protocol-defined inclusion/exclusion criteria may apply

Other exclusion criteria may apply.



Research Study Number       20110186
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Hematologic Malignancies; Lymphoma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.